AI-designed protein ‘off switch’ could tame cancer drugs

AI-engineered protein switch enables precise control of cancer drug activity

The University of Washington’s Institute for Protein Design has made a breakthrough in controlling drug activity: using AI and computational protein design, researchers created a molecular “off switch” that can rapidly deactivate interleukin-2 (IL-2) after it has already activated immune cells. This advance could significantly improve safety and precision in cancer immunotherapy.

IL-2 is a powerful cytokine used to stimulate immune response in cancers such as melanoma and kidney cancer, but its side effects can be dangerous when the immune system is overstimulated. The new switchable system offers a second lever — not just dose, but duration — by engineering proteins that can induce dissociation of an active drug complex on command.

How the switch works

The design hinges on a concept called facilitated dissociation. Instead of simply adjusting how tightly a drug binds to its target, the researchers engineered a host protein fused to a conformational switch. When an effector molecule is introduced, it triggers a structural change that destabilizes the drug-target complex, causing it to fall apart quickly.

In lab experiments, interactions that would normally persist for 20 minutes disassociated in as little as 10 seconds when the effector was applied.

By applying this method to IL-2 — used in cancer therapy — the team created a switchable IL-2 molecule that could stimulate immune cells and then be shut down on demand.

Implications and broader applications

This innovation offers several potential advantages:

• Greater safety in immunotherapy: Physicians could terminate harmful immune activation immediately if side effects arise.
• High-dose short bursts: Drugs could be delivered in powerful pulses but deactivated quickly to limit toxicity.
• Expanding to diagnostics: The same design principle was used to engineer a bioluminescent enzyme switch, leading to a coronavirus sensor that responds ~70× faster than conventional protein tests.
• Collaborative efforts spanned labs at UW, Osnabrück University, Stanford, and Oregon Health & Science University.

Challenges ahead

Despite promise, the technology is still at the laboratory stage. Translating switchable proteins to human therapies will require rigorous safety testing, optimization of delivery, and regulatory approval. As David Baker (2024 Nobel Laureate) noted, this work adds an extra dial of control, how long a drug is active, which could transform future medicines.

A glimpse into the future of precision medicine

By adding this temporal control layer, scientists now have richer control over biological therapies. The ability to turn molecular activity on and off on demand could lead to smarter, safer therapeutics — from cancer immunotherapy to biosensors and beyond.

Stay informed and protect your health!

CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for expert tips, health updates, and the latest medical research straight to your phone.